[Form 4] Supernus Pharmaceuticals, Inc. Insider Trading Activity
Insider transactions at Supernus Pharmaceuticals (SUPN): Sr. VP of IP and CSO Padmanabh P. Bhatt reported a net change in holdings tied to stock compensation and disposition activity. The reporting form shows a disposition of 13,049 shares of Common Stock and an acquisition of 1,250 performance share units (PSUs) that correspond to 1,250 underlying common shares, both reported with a transaction date of 08/07/2025. The 13,049-share figure includes 345 shares acquired through the company’s Employee Stock Purchase Plan. The PSUs were originally awarded on 02/23/2023 with performance objectives set on 06/12/2023, and a portion vested upon satisfaction of those objectives.
Insider transactions at Supernus Pharmaceuticals (SUPN): Il Sr. VP di IP e CSO Padmanabh P. Bhatt ha riportato una variazione netta delle partecipazioni legata a compensi azionari e operazioni di cessione. Il modulo di segnalazione mostra una disposizione di 13,049 azioni di Common Stock e un'acquisizione di 1,250 performance share units (PSU) corrispondenti a 1,250 azioni ordinarie sottostanti, entrambe con data di transazione 08/07/2025. Le 13,049 azioni includono 345 azioni ottenute tramite l'Employee Stock Purchase Plan dell'azienda. Le PSU erano state originariamente assegnate il 02/23/2023 con obiettivi di performance fissati il 06/12/2023, e una parte è maturata al soddisfacimento di tali obiettivi.
Insider transactions at Supernus Pharmaceuticals (SUPN): El vicepresidente senior de IP y CSO Padmanabh P. Bhatt informó un cambio neto en sus participaciones vinculado a compensación en acciones y operaciones de disposición. El formulario de notificación muestra una disposición de 13,049 acciones de Common Stock y una adquisición de 1,250 unidades de acciones por rendimiento (PSU) equivalentes a 1,250 acciones ordinarias subyacentes, ambas con fecha de transacción 08/07/2025. Las 13,049 acciones incluyen 345 acciones adquiridas a través del Employee Stock Purchase Plan de la compañía. Las PSU fueron originalmente otorgadas el 02/23/2023 con objetivos de rendimiento establecidos el 06/12/2023, y una parte se consolidó al cumplirse dichos objetivos.
Insider transactions at Supernus Pharmaceuticals (SUPN): 지적재산권 담당 수석부사장이자 최고과학책임자(CSO)인 Padmanabh P. Bhatt가 주식 보상 및 처분 활동과 관련한 보유 변동을 신고했습니다. 신고서에는 Common Stock 13,049주 처분 및 기초 보통주 1,250주에 해당하는 1,250 성과주 단위(PSU) 취득이 기재되어 있으며, 두 거래의 거래일은 모두 08/07/2025로 표기되어 있습니다. 13,049주에는 회사의 직원 주식 매입 제도를 통해 취득한 345주가 포함되어 있습니다. 해당 PSUs는 원래 02/23/2023에 수여되었고, 성과 목표는 06/12/2023에 설정되었으며 일부는 그 목표 충족 시에 베스팅되었습니다.
Insider transactions at Supernus Pharmaceuticals (SUPN): Le vice-président senior en PI et directeur scientifique Padmanabh P. Bhatt a déclaré une variation nette de ses avoirs liée à des rémunérations en actions et à des opérations de cession. Le formulaire de déclaration indique une cession de 13,049 actions de Common Stock et une acquisition de 1,250 unités d'actions de performance (PSU) correspondant à 1,250 actions ordinaires sous-jacentes, les deux opérations portant la date de transaction 08/07/2025. Les 13,049 actions comprennent 345 actions acquises via le Employee Stock Purchase Plan de la société. Les PSU ont été initialement attribuées le 02/23/2023 avec des objectifs de performance fixés le 06/12/2023, et une partie a été acquise lors de la réalisation de ces objectifs.
Insider transactions at Supernus Pharmaceuticals (SUPN): Der Senior VP für IP und CSO Padmanabh P. Bhatt meldete eine Nettoänderung seiner Bestände im Zusammenhang mit Aktienevergütung und Veräußerungen. Das Meldeformular weist eine Veräußerung von 13,049 Aktien der Common Stock sowie eine Erwerb von 1,250 Performance Share Units (PSUs) aus, die 1,250 zugrundeliegenden Stammaktien entsprechen; beide Transaktionen sind mit dem Datum 08/07/2025 angegeben. Die 13,049 Aktien enthalten 345 Aktien, die über das Employee Stock Purchase Plan des Unternehmens erworben wurden. Die PSUs wurden ursprünglich am 02/23/2023 gewährt, die Performance-Ziele wurden am 06/12/2023 festgelegt, und ein Teil wurde beim Erreichen dieser Ziele fällig.
- Acquisition of 1,250 PSUs reflecting vested performance-based compensation from the February 23, 2023 award
- Disclosure includes 345 ESPP shares, showing employee-plan participation and transparency about acquisition sources
- Disposition of 13,049 common shares by a senior officer, indicating insider liquidity that may reduce insider ownership
Insights
TL;DR: Insider reported a sizeable sale and concurrent vesting-related grant conversion; appears routine compensation and disposition activity.
The Form 4 discloses a disposition of 13,049 common shares and the acquisition of 1,250 PSUs tied to prior awards. The filing explicitly notes 345 ESPP shares included in the aggregate. These entries reflect recognized equity compensation mechanics: PSUs awarded in 2023 with performance objectives set in June 2023 that subsequently vested and converted to underlying shares. From a market-impact viewpoint the filing documents insider liquidity and standard compensation realization rather than an undisclosed corporate event.
TL;DR: Transaction shows exercised/vested equity and an outright disposition; governance disclosure appears complete and typical.
The reporting individual, identified as an officer (Sr. VP of IP, CSO), reported both share dispositions and PSU acquisitions on the same transaction date. The Form 4 includes the required explanatory notes: ESPP purchases and the original PSU award date and performance objective date. The submission is signed by an attorney-in-fact, consistent with delegated filing practice. The disclosure provides the core elements stakeholders expect for insider equity events.
Insider transactions at Supernus Pharmaceuticals (SUPN): Il Sr. VP di IP e CSO Padmanabh P. Bhatt ha riportato una variazione netta delle partecipazioni legata a compensi azionari e operazioni di cessione. Il modulo di segnalazione mostra una disposizione di 13,049 azioni di Common Stock e un'acquisizione di 1,250 performance share units (PSU) corrispondenti a 1,250 azioni ordinarie sottostanti, entrambe con data di transazione 08/07/2025. Le 13,049 azioni includono 345 azioni ottenute tramite l'Employee Stock Purchase Plan dell'azienda. Le PSU erano state originariamente assegnate il 02/23/2023 con obiettivi di performance fissati il 06/12/2023, e una parte è maturata al soddisfacimento di tali obiettivi.
Insider transactions at Supernus Pharmaceuticals (SUPN): El vicepresidente senior de IP y CSO Padmanabh P. Bhatt informó un cambio neto en sus participaciones vinculado a compensación en acciones y operaciones de disposición. El formulario de notificación muestra una disposición de 13,049 acciones de Common Stock y una adquisición de 1,250 unidades de acciones por rendimiento (PSU) equivalentes a 1,250 acciones ordinarias subyacentes, ambas con fecha de transacción 08/07/2025. Las 13,049 acciones incluyen 345 acciones adquiridas a través del Employee Stock Purchase Plan de la compañía. Las PSU fueron originalmente otorgadas el 02/23/2023 con objetivos de rendimiento establecidos el 06/12/2023, y una parte se consolidó al cumplirse dichos objetivos.
Insider transactions at Supernus Pharmaceuticals (SUPN): 지적재산권 담당 수석부사장이자 최고과학책임자(CSO)인 Padmanabh P. Bhatt가 주식 보상 및 처분 활동과 관련한 보유 변동을 신고했습니다. 신고서에는 Common Stock 13,049주 처분 및 기초 보통주 1,250주에 해당하는 1,250 성과주 단위(PSU) 취득이 기재되어 있으며, 두 거래의 거래일은 모두 08/07/2025로 표기되어 있습니다. 13,049주에는 회사의 직원 주식 매입 제도를 통해 취득한 345주가 포함되어 있습니다. 해당 PSUs는 원래 02/23/2023에 수여되었고, 성과 목표는 06/12/2023에 설정되었으며 일부는 그 목표 충족 시에 베스팅되었습니다.
Insider transactions at Supernus Pharmaceuticals (SUPN): Le vice-président senior en PI et directeur scientifique Padmanabh P. Bhatt a déclaré une variation nette de ses avoirs liée à des rémunérations en actions et à des opérations de cession. Le formulaire de déclaration indique une cession de 13,049 actions de Common Stock et une acquisition de 1,250 unités d'actions de performance (PSU) correspondant à 1,250 actions ordinaires sous-jacentes, les deux opérations portant la date de transaction 08/07/2025. Les 13,049 actions comprennent 345 actions acquises via le Employee Stock Purchase Plan de la société. Les PSU ont été initialement attribuées le 02/23/2023 avec des objectifs de performance fixés le 06/12/2023, et une partie a été acquise lors de la réalisation de ces objectifs.
Insider transactions at Supernus Pharmaceuticals (SUPN): Der Senior VP für IP und CSO Padmanabh P. Bhatt meldete eine Nettoänderung seiner Bestände im Zusammenhang mit Aktienevergütung und Veräußerungen. Das Meldeformular weist eine Veräußerung von 13,049 Aktien der Common Stock sowie eine Erwerb von 1,250 Performance Share Units (PSUs) aus, die 1,250 zugrundeliegenden Stammaktien entsprechen; beide Transaktionen sind mit dem Datum 08/07/2025 angegeben. Die 13,049 Aktien enthalten 345 Aktien, die über das Employee Stock Purchase Plan des Unternehmens erworben wurden. Die PSUs wurden ursprünglich am 02/23/2023 gewährt, die Performance-Ziele wurden am 06/12/2023 festgelegt, und ein Teil wurde beim Erreichen dieser Ziele fällig.
FAQ
What did the Form 4 for Supernus (SUPN) report?
Who filed the Form 4 for SUPN and what is their role?
Do the PSUs relate to a prior award?
Does the filing mention purchases through an employee plan?
Was the Form 4 submitted by the reporting person directly?
